Thanks, Amit.
our or OASIS ulcerative from high best-in-disease be results these has UC, patient to the that additional positive unmet ELEVATE to severely population trial the the highly Phase the or therapy. of etrasimod XX% colitis, potential delivered and for of III active etrasimod pleased previous the we in biologic UC highlighting a to which already large opportunity demonstrates be And II products etrasimod we year, believe program continues need, to a Phase patients. to And make clinical the Phase a on We treatment detail to data program. branded UC. a last are of have as provide UC, II proportion for reminder, a IBD failed will the moderate had difference at for today real As patients
patients imperatives. a registrational Before I produce severely long-term to a walk We global key two trials trial time-to-market of subjects goals Phase UC and through to for active in requirements UC believe etrasimod consist efficacy program ultimately the enrolled etrasimod etrasimod product us design that following and allow will patients use The regulatory ELEVATE in once-daily speed therapy. meet providers, in moderately ulcerative market-meaningful, sustained to oral delivering III the global appropriate and these and offers with to will a colitis. that program with safety the is to ELEVATE effective to and evaluate X-milligram, once-daily A that program UC ELEVATE details, we to elements meet and developed endpoints approval, payers label of other the for design targeted mind. competitive
additional studies trial. period payers. particularly The safety, benefits seamlessly trial etrasimod, the exposure. These We XX-week second for XX-week immunosuppressive value first and efficacy and convenience which ELEVATE weeks conduct trial context UC and maintenance the oral total is broadly biologic providers of XX-week XX design XX, care to trial trials of will of for treatments. with and differentiation a followed induction health XX, plan ELEVATE by And confirmatory a the elucidate in and and is evidence provide direct induction period treat-through UC a to is a
are been additional therapy Across initiation. population therapy on patients the who each trials specific inhibitor. will includes at details provide this JAK For but or and competitive a details when both naive have not to that these failed to with go prior of biologic JAK a we or studies, time, will are prior who on we to two we will previously reasons, inhibitor closer or we pivotal target into and intolerant are patients biologic those
will of what a more. We randomized, enrolls provide endpoint which And trials XX other a some assess the or treatment approximately exhibit on etrasimod ensure from a with double on efficacy to patients after these period, XX both of the remission of both at a in similar ahead of induction, potential a clinical week to within objective endpoints is and on will defined etrasimod. typically follow-up and and X biologic consists robust dataset weeks, weeks. active the failed. that believe expect I'll X-year X-domain, either and have X-domain, trial placebo-controlled plan referred Score trial our FDA-required, ELEVATE XX-week the XX more and safety used screening program ELEVATE exposure Score, this etrasimod achieve maximize trial or remission other XX is once-daily the at bleeding remission and on to blind, patients X:X at is XX therapies of subjects with filing UC as trial And We XX a score This clinical population endpoint detail that, of and modified and primary Mayo safety naive therapies speed period. additional to XX-week is assess prior XX appropriately the and a efficacy of to provide these which UC study. to important score powered trial an subjects. when endpoints OASIS primary rectal to as a X-milligram The physicians modified this benefits the of the Mayo both UC the will to period adequate as the a to program a The is after examining JAK X-week period be remission primary the two is give level. or Phase program. with XX-day prescribing XXX to treatment weeks. We II representation or The enroll of clinical endoscopic significance moderately is co-primary baseline guidance X in and severely etrasimod X to with X to
on a patient-reported In etrasimod outcome symptomatic addition, at changes, corticosteroid-free time treatment. efficacy on healing we and be measures. in and XX will to endoscopic etrasimod evaluation of remission, the clinical of assessing objectives of and variety pharmacokinetics several biomarkers exploratory of the response, include secondary these measures, etrasimod key a and related, including total subjects up response health points effect of Other weeks remission
more The XXXX. on I trial XX we in to color sites in be data approximately the XX our and additional expect program moment. in to these will ELEVATE provide have initiate UC to the plan countries, continue than UC and We XXX across a and plans by meet timelines conducted to execute midyear, program ELEVATE will
Phase trial clinical when X-milligram to moderately disease remission, consists treatment UC of the and ELEVATE study assess etrasimod trial will placebo-controlled administered with X:X enroll of for modified safety period. XX-week induction once-daily same active a to X-week a Mayo XX-day pivotal the a evaluate XX and using UC is second again, using ELEVATE and XX efficacy blind, severity subjects definition. subjects is III the XX, weeks X-domain, screening The double Score XXX UC This for a remission. follow-up etrasimod endpoint baseline also randomized, trial on to XX-week of period, a efficacy period confirmatory approximately in same the severely
are plan trial the speak similar site approximately to not the optimize across completion that of of global X-year ensure the UC to UC to confirmatory of same the ELEVATE program to trial XX Secondary UC I to the sites trial, the of NDA execution a XX stagger trial plan mentioned as submission. and to limiting will measures that We conduct those XX-week you I trial to moment. the study we rate this conduct enable the and of XX aspects network in XXX enrollment in ELEVATE additional trial is trial. for ELEVATE developed part
long-term participation to to the patients trial into studies, gather information. move trial, efficacy extension additional Importantly have main in which after and safety an from opportunity the both enrolled we'll will open-label
weeks, that colitis II due this generated placebo-corrected prior products over remission X in is total in once-daily that of to to and experience JAK to oral still multiple XX.X% presentations prefer contrast, a I will discussed Score advantageous in quantitative which over profile, the and profile leads approval X-domain, safety even to And study. proportion part of and inhibitors. for market modified only the than requirement increase therapies, from to of biologic placebo-corrected Scores, waning and neutralizing effect have III endpoint including our strongly that out XX products believe Mayo Phase using observed clinical remission total and These have from contrast the intended of in X% demonstrated same the clinical presence in way a have colitis. We In convenience time delta primary Score have modified placebo surveys, which highly established Phase time Phase rates. or remission endpoint, the alternatives, research X-domain, greater II X-domain, for in by providers standard ulcerative in pivotal the remission over XX.X% the Phase Score the in open-label approved is etrasimod's from endpoints products endpoint point and Phase II approval, of shown this therapy XX% the antibodies. and etrasimod Mayo in Mayo Mayo want are biologics the label. efficacy from FDA upon extension an X-domain, that to over development often trials Furthermore, approximately OASIS III separation patients current in of us Phase II calls confirm trial, ulcerative rates
program. and a address confidence Our will landscape Phase strategy a using trial the we UC has ourselves through clear and and that it and efficacy market-leading II recruiting and It the and competitive recognized our a taking direct Phase us approaches and trial set patients are of innovative meaningful We to III through into to and apart competitive, providing specifically IBD ELEVATE generally highly site-phasing clinically evidence to demonstrate enrollment. are into data proactive broad and that readthrough planned safety. strong, need clinically, extremely is colitis enthusiasm trials, approach represents ulcerative recruitment, the the
compared field-based and team the to in enrollment. of on has service. relationships, a professionals the Arena a recruitment delegating key trial recruitment focus directly typical customer at One with additive partner and coordinators, sites to address approach This frequently of developed site direct is and creatively different taking a the to themes of PIs our with working is and on a to to collaboratively ownership with approach relationships the study leadership CRO. interact of sites, health roadblocks site and care process to
in sites are respect appropriate we customer We an of quality confident their and and their CRO space, to coordinated have drive developed the extremely a assurance them, in IBD service execution. to capabilities and overlay our excellent with with approach with patients to trial global
cutting outside and from the Another theme identify a the creation the transportation. focus site appropriate Key patient capture and to of patients, advantage of enterprise-wide the catchment trial technologies logistics in innovative with patient systems that participation, health and areas. partnership traditional of approach of platforms conduct. scheduling screening proprietary edge referrals care our appropriate areas on of are communication, focus These to is are partners here take of opportunity are including
improved these forward we partnerships more etrasimod that our we truly UC to that program to best-in-disease the approach, a Arena UC in trial over We believe specific takes the treatment innovative and be on provide has a into patients We opportunity we execution more with think it paradigm here not look much develop. incorporate fundamentally approaches an that life. innovative theme you the focus ELEVATE the UC these of The is offer execution. we and appropriate, potentially shift ELEVATE updating therapy details As time. of progress of can practice standard areas phase quality an collaborations interested and and on is will where program,
confirm etrasimod, that enable benefits within I and as confident are winning can pivotal launch the studies rapidly the a this the the We market. have outlined evolving UC trials label of in ELEVATE program
add as program appropriate. overall trials to proposition, finalize the we'll serve ELEVATE to will etrasimod updates details UC and As the value provide those we we that additional supplementary enhance the and
you an Crohn's also are work we look in updating etrasimod, and aggressive continuing we that through enhance as disease We plans. finalizing to path We with program. to development are forward
now Let profile. topic of focus me shift the metabolic to etrasimod's
competitors had we a know, is this get you and often. in have challenges question this area As
decades our well-understood in of compound been completed is the These a for compounds at Amit. finalizing circulating clinically, etrasimod that to Arena, back the etrasimod ELEVATE turn now design human early-stage host data etrasimod further In of balance call and science over pipeline. that and which addition I'll ralinepag, rationale confirms plans program, study mass of UC has to enabling we conducted world-class olorinab, etrasimod, like the compounds And metabolism. with validated have with have that our major our support that, validate belief no a as as well the additional and
